Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...

A successful clinical trial requires an effective randomization strategy formulated by innovative thinking to meet unique demands. In a recent webinar, Solventum revealed how the eClinical platform ...

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.

Olomorasib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Non-Small Cell Lung Cancer.

Ponsegromab is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Cancer Anorexia-Cachexia Syndrome.

Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.

Lepodisiran sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase III program in Atherosclerosis.

China’s NMPA has granted approval to Santhera Pharmaceuticals’ AGAMREE, used in treating DMD in individuals aged four years and above.

Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

Zelicapavir is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase II program in Respiratory Syncytial Virus (RSV) Infections.

Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy.